PMID- 31290126
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201124
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 5
DP  - 2019 Oct
TI  - SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into 
      Practice.
PG  - 1595-1622
LID - 10.1007/s13300-019-0657-8 [doi]
AB  - Cardiovascular disease (CVD), including heart failure (HF), is a leading cause of 
      morbidity and mortality in people with type 2 diabetes mellitus (T2DM). CVD and 
      T2DM share common risk factors for development and progression, and there is 
      significant overlap between the conditions in terms of worsening outcomes. In 
      assessing the cardiovascular (CV) safety profiles of anti-diabetic drugs, 
      sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapies have emerged with 
      robust evidence for reducing the risk of adverse CVD outcomes in people with T2DM 
      who have either established CVD or are at risk of developing CVD. A previous 
      consensus document from the Improving Diabetes Steering Committee has examined 
      the potential role of SGLT2is in T2DM management and considered the risk-benefit 
      profile of the class and the appropriate place for these medicines within the 
      T2DM pathway. This paper builds on these findings and presents practical guidance 
      for maximising the pleiotropic benefits of this class of medicines in people with 
      T2DM in terms of reducing adverse CVD outcomes. The Improving Diabetes Steering 
      Committee aims to offer evidence-based practical guidance for the use of SGLT2i 
      therapies in people with T2DM stratified by CVD risk. This is of particular 
      importance currently because some treatment guidelines have not been updated to 
      reflect recent evidence from cardiovascular outcomes trials (CVOTs) and 
      real-world studies that complement the CVOTs. The Improving Diabetes Steering 
      Committee seeks to support healthcare professionals (HCPs) in appropriate 
      treatment selection for people with T2DM who are at risk of developing or have 
      established CVD and examines the role of SGLT2i therapy for these people.Funding: 
      Napp Pharmaceuticals Limited.
FAU - Ali, Amar
AU  - Ali A
AD  - Oakenhurst Medical Practice, Blackburn, UK.
FAU - Bain, Steve
AU  - Bain S
AD  - Diabetes Research Unit Cymru, Swansea University, Swansea, UK.
FAU - Hicks, Debbie
AU  - Hicks D
AD  - Medicus Health Partners, Enfield, UK.
FAU - Newland Jones, Phillip
AU  - Newland Jones P
AD  - University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
FAU - Patel, Dipesh C
AU  - Patel DC
AD  - Department of Diabetes and Endocrinology, Division of Medicine, University 
      College London, London, UK.
FAU - Evans, Marc
AU  - Evans M
AD  - Department of Diabetes, University Hospital Llandough, Llandough, UK.
FAU - Fernando, Kevin
AU  - Fernando K
AD  - North Berwick Health Centre, North Berwick, UK.
FAU - James, June
AU  - James J
AD  - University Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Milne, Nicola
AU  - Milne N
AD  - CODES (Community Diabetes Education and Support), Manchester University NHS 
      Foundation Trust, Manchester, UK.
FAU - Viljoen, Adie
AU  - Viljoen A
AD  - Department of Metabolic Medicine/Chemical Pathology, Lister Hospital, Stevenage, 
      UK.
FAU - Wilding, John
AU  - Wilding J
AUID- ORCID: 0000-0003-2839-8404
AD  - Obesity and Endocrinology Research, University of Liverpool, Liverpool, UK. 
      J.P.H.Wilding@liverpool.ac.uk.
CN  - As part of The Improving Diabetes Steering Committee
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190709
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
EIN - Diabetes Ther. 2019 Jul 18;:. PMID: 31321747
PMC - PMC6778582
OTO - NOTNLM
OT  - Anti-diabetic medicines
OT  - Cardiovascular disease (CVD)
OT  - Clinical guidance
OT  - Heart failure (HF)
OT  - Oral glucose-lowering medicines
OT  - Practical treatment selection
OT  - SGLT2 inhibitors (SGLT2i)
OT  - Therapy choice
OT  - Type 2 diabetes mellitus (T2DM)
EDAT- 2019/07/11 06:00
MHDA- 2019/07/11 06:01
PMCR- 2019/07/09
CRDT- 2019/07/11 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/07/11 06:00 [pubmed]
PHST- 2019/07/11 06:01 [medline]
PHST- 2019/07/11 06:00 [entrez]
PHST- 2019/07/09 00:00 [pmc-release]
AID - 10.1007/s13300-019-0657-8 [pii]
AID - 657 [pii]
AID - 10.1007/s13300-019-0657-8 [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Oct;10(5):1595-1622. doi: 10.1007/s13300-019-0657-8. Epub 
      2019 Jul 9.